[The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
The data obtained by the authors suggest that lipanor may correct those lipid metabolic disturbances that are most pronounced in each individual case. Moreover, the above drug is capable of lowering substantially the level of total blood cholesterol and atherogenic fractions of lipoproteins as early as at day 14 after its intake. Being associated with minimum adverse effects, and intended to be taken on a once-daily schedule, the drug will, we believe, come in wide use.
Tashchuk
V K
VK
Makoviĭchuk
I O
IO
Bilets'kyĭ
S V
SV
Hrechko
S I
SI
Polishchuk
O Iu
OIu
Turubarova
N A
NA
D002908:Chronic Disease; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D058607:Fibric Acids; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008055:Lipids; D002995:Clofibric Acid; C019304:ciprofibrate